Total RNA was extracted from normal and FECD HCEC-DM complexes (samples 13–15,
Table 1 ) as recommended by the manufacturer (TRIzol; Invitrogen). Samples were purified from DNA contamination by treating them with amplification grade DNase I (Invitrogen). RNA quantity and quality were assessed by spectrophotometric analysis. For all samples, cDNA was prepared by reverse transcription with a commercially available kit (Promega, Madison, WI). Relative expression levels of
TGFBI were assessed by real-time PCR with a sequence-detection system (ABI Prism model 7900 HT; Applied Biosystems Inc., [ABI] Foster City, CA). Primers and probes for
TGFBI (
TaqMan Gene Expression Assays; Invitrogen) and for the endogenous control β
2-microglobulin (β
2-MG; human B2M endogenous control, FAM/MGB probe,
TaqMan Endogenous Controls) were obtained from ABI. Samples (
n = 3) were assayed in duplicate in a total volume of 50 μL, using thermal cycling conditions of 2 minutes at 50°C and 10 minutes at 95°C followed by 50 cycles of 95°C for 15 seconds and 60°C for 1 minute. No-template controls were run in each assay to confirm lack of contamination in reagents used for amplification. For data analysis, the comparative threshold cycle (C
T) method was adopted with the relative mRNA levels in normal subjects selected as the calibrator. The C
T was set in the exponential phase of the amplification plot. To normalize the amount of target gene in each sample, the change in C
T (ΔC
T) was calculated by subtracting the average C
T of the endogenous control from that of the target gene. The amount of
TGFBI mRNA in FECD was expressed relative to the amount present in the calibrator, using the formula 2
−ΔΔCT. Results were averaged, and the SEM was calculated. Statistical analysis with Student’s unpaired
t-test was performed (Excel 2002 for Windows XP; Microsoft).
P < 0.05 was considered to be significant.